Clinical trials: Bronchial Neoplasms
Oncogene-addicted Non Small Cell Lung Cancer, Early-stage Operable Non Small Cell Lung Cancer
Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer
This study aims to determine if it is feasible to collect samples of blood and viable lung cancer tissue in patients with either: Stage IV mutation-driven NSCLC Stage II-III NSCLC undergoing neoadjuvant immunotherapy prior to…
- Conditions
- Oncogene-addicted Non Small Cell Lung Cancer, Early-stage Operable Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- FeStival (NCT07008742)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-small Cell Lung Cancer, Brain Metastases
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.
- Trial name
- NCT01516983
- Testing
- icotinib, Whole brain radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small- Cell Lung Cancer (NSCLC)
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-mutated unresectable or metastatic non-small-cell lung cancer (NSCLC).
- Trial name
- NCT05141786
- Testing
- MRG002
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Miracogen Inc.
Non-small Cell Lung Cancer Stage I
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
This is a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel…
- Trial name
- NCT03603002
- Testing
- Post-SABR Biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer, Metastatic Cancer
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.
- Trial name
- NCT01514877
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
- Trial name
- LungTIME-C01 (NCT05549037)
- Testing
- Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer, Artificial Intelligence (AI) in Diagnosis
AI-Based Prediction of Stage and Survival in Non-Small Cell Lung Cancer: A Retrospective Study
This study aims to evaluate the role of artificial intelligence (AI) in predicting disease stage and survival in patients diagnosed with non-small cell lung cancer (NSCLC).
- Trial name
- NCT07068139
- Testing
- AI-Based Predictive Modeling
- Volunteers
- 156 people
- Sponsor
- Hilkat Fatih Elverdi
Carcinoma, Non-Small-Cell Lung
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors.
- Trial name
- NCT00130780
- Testing
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
- Trial name
- NCT02635061
- Testing
- ACY-241, Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Celgene
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
This phase II trial investigates how stereotactic radiosurgery affects brain functions while treating patients with small cell lung cancer that has spread to the brain (brain metastasis).
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04516070
- Testing
- Questionnaire Administration, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Non Small Cell Lung Cancer
Detection of Circulating Biomarkers of Immunogenic Cell Death
In this exploratory study, the investigators will investigate if markers (molecular and immunological) of ICD or anti-tumor immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy…
- Trial name
- ICD (NCT02921854)
- Testing
- Blood withdrawal
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht Radiation Oncology
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This phase II clinical trial studies how well combining different regimens of chemotherapy and gefitinib with radiation therapy work in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00040794
- Testing
- paclitaxel, carboplatin, gefitinib
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if MEDI4736 given in combination with selumetinib can help to control advanced lung cancer. The safety of this drug combination will also be studied.
- Conditions
- Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer, Recurrent Nonsmall Cell Lung Cancer
- Trial name
- NCT03004105
- Testing
- Selumetinib, Durvalumab, Phone Calls
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.